3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Lymphoma, Non-Hodgkin
5
Lymphoma, Large B-Cell, Diffuse
4
Recurrence
3
Myeloproliferative Disorders
3
Lymphoma
3
Primary Myelofibrosis
2
Lymphoma, Follicular
2
Lymphoma, B-Cell, Marginal Zone
2
Lymphoma, T-Cell, Peripheral
1
Lymphoma, Mantle-Cell
1
Lymphoma, B-Cell
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Leukemia
1
Interventions
venetoclax
69
Cyclophosphamide
53
ibrutinib
45
obinutuzumab
43
acalabrutinib
43
Rituximab
40
fludarabine
37
fludarabine phosphate
30
Specimen Handling
29
pirtobrutinib
26
Biopsy
24
zanubrutinib
23
Whole-Body Irradiation
16
Bendamustine Hydrochloride
15
Magnetic Resonance Spectroscopy
14
Mycophenolic Acid
13
Lenalidomide
11
Peripheral Blood Stem Cell Transplantation
9
Sirolimus
8
idelalisib
7
Tacrolimus
7
CT-P10
7
ARQ531
7
tafasitamab
6
Prednisone
6
Busulfan
6
pembrolizumab
5
Stem Cell Transplantation
5
Melphalan
5
Interleukin-2
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Leukemia, Lymphocytic, Chronic, B-Cell
×
parsaclisib
×
1 year
×
Clear all
NCT04809467
2026-02-04
topMIND
Incyte Corporation
Phase 1/2
Terminated
54 enrolled
23 charts